Neb Obradovic
@Cormorant Asset Management, Lp
Latest period2024 - Q3ReportedManaged Assets$1.886BTotal holdings45
Assets growth rate8.94%Assets growth rate (2-Q avg)-7.56%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Cormorant Asset Management, Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 45 positions.
Assets under management
The assets under management (AUM) of Cormorant Asset Management, Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.886B in assets, with a quarterly growth rate of 8.94% and a 2-quarter average growth rate of -7.56%. The portfolio is managed by Neb Obradovic, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
MLTXMoonlake Immunotherapeutics
| 22.72% | $428.275M 8.494M shares@ $50.42 avg price | |
PCVXVaxcyte Inc
| 6.06% | $114.27M 1M shares@ $114.27 avg price | Decreased -9.09% |
ACLXArcellx Inc
| 5.54% | $104.388M 1.25M shares@ $83.51 avg price | Decreased -18.03% |
LBPHLongboard Pharmaceuticals In
| 4.94% | $93.006M 2.79M shares@ $33.33 avg price | |
EWTXEdgewise Therapeutics Inc
| 4.83% | $90.92M 3.407M shares@ $26.69 avg price | Increased 13.31% |
EYPTEyepoint Pharmaceuticals Inc
| 3.53% | $66.517M 8.325M shares@ $7.99 avg price | |
RAPPRapport Therapeutics Inc
| 3.2% | $60.23M 2.941M shares@ $20.48 avg price | Increased 0.03% |
CRNXCrinetics Pharmaceuticals In
| 2.99% | $56.21M 1.1M shares@ $51.1 avg price | Decreased -18.51% |
PRAXPraxis Precision Medicines I
| 2.66% | $50.06M 870,000 shares@ $57.54 avg price | Increased 27.01% |
CRBPCorbus Pharmaceuticals Hldgs
| 2.6% | $48.996M 2.375M shares@ $20.63 avg price | Increased 17.29% |